IE
IRWD icon

Israel Englander’s Ironwood Pharmaceuticals IRWD Stock Holding History

Israel Englander’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150,100
Closed -$1.45M – 6297
2023
Q3 		$1.45M Buy
+150,100
New +$1.47M ﹤0.01% 3879

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Israel Englander's IRWD Position: Q2 2026 in Review

Israel Englander sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2026, closing a stake of 457,114 shares — an estimated $1.6M sold.

Israel Englander first reported a position in IRWD in Q2 2013 and held it in 50 quarters. The position peaked at $65.4M in Q1 2014. 211 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Israel Englander reported no remaining Ironwood Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 457,114 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
  • Israel Englander first reported a position in Ironwood Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Israel Englander's Ironwood Pharmaceuticals position peaked at $65.4M in Q1 2014.
  • 211 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.